Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.69 |
| ▸ | PPARD | Q03181 | 9/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449531 | 0.97 | FFAR1 (0.70) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL3451166 | 0.94 | PPARD (0.69) | FFAR1PPARDPPARAFFAR4 | |
| SCHEMBL13110407 | 0.88 | FFAR1 (0.61) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL4622248 | 0.86 | FFAR1 (0.68) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL13110431 | 0.86 | FFAR1 (0.61) | FFAR1PPARDPPARAPPARGFFAR4 | |
| SCHEMBL3450821 | 0.85 | FFAR1 (0.72) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3962238 | 0.84 | PPARD (0.74) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3965769 | 0.84 | PPARD (0.74) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL3962234 | 0.84 | PPARD (0.74) | FFAR1PPARDPPARAPPARG | |
| SCHEMBL12214666 | 0.83 | PPARD (0.75) | FFAR1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | FFAR1 93/4885PPARD 74/4885PPARA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.